NCT07047118
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07047118
Title A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Recruitment Active, not recruiting
Gender male
Phase Phase II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | NLD | ITA | ISR | FRA | ESP | DEU | CZE | CAN | AUT | AUS

Facility Status City State Zip Country Details
City of Hope National Medical Duarte California 91010 United States Details
Providence Saint Johns Health Ctr Santa Monica California 90404 United States Details
Rocky Mountain Cancer Centers Denver Colorado 80218 United States Details
Yale University School Of Medicine New Haven Connecticut 06520 United States Details
Indiana University Indianapolis Indiana 46202 United States Details
Massachusetts General Hospital Boston Massachusetts 02114 United States Details
XCancer Omaha LLC Omaha Nebraska 68130 United States Details
NYU Laura and Isaac Perlmutter Cancer Center New York New York 10016 United States Details
Univ of Pittsburgh Cancer Institute Pittsburgh Pennsylvania 15232 United States Details
Texas Oncology Sammons Cancer Center Dallas Texas 78246 United States Details
Urology San Antonio San Antonio Texas 78229 United States Details
Novartis Investigative Site Darlinghurst New South Wales 2010 Australia Details
Novartis Investigative Site Adelaide South Australia 5000 Australia Details
Novartis Investigative Site Melbourne Victoria 3004 Australia Details
Novartis Investigative Site Innsbruck Tyrol 6020 Austria Details
Novartis Investigative Site Linz 4020 Austria Details
Novartis Investigative Site Vienna 1090 Austria Details
Novartis Investigative Site Burnaby British Columbia V5G 4P3 Canada Details
Novartis Investigative Site Montreal Quebec H3T 1E2 Canada Details
Novartis Investigative Site Beijing 100034 China Details
Novartis Investigative Site Beijing 100036 China Details
Novartis Investigative Site Olomouc 779 00 Czechia Details
Novartis Investigative Site Prague 150 06 Czechia Details
Novartis Investigative Site Brest 29200 France Details
Novartis Investigative Site Marseille 13273 France Details
Novartis Investigative Site Tours 37044 France Details
Novartis Investigative Site Essen 45147 Germany Details
Novartis Investigative Site Rostock 18057 Germany Details
Novartis Investigative Site Afula 1834111 Israel Details
Novartis Investigative Site Beersheba 8457108 Israel Details
Novartis Investigative Site Haifa 3109601 Israel Details
Novartis Investigative Site Jerusalem 9103102 Israel Details
Novartis Investigative Site Petah Tikva 4941492 Israel Details
Novartis Investigative Site Ramat Gan 5265601 Israel Details
Novartis Investigative Site Genova GE 16132 Italy Details
Novartis Investigative Site Roma RM 00128 Italy Details
Novartis Investigative Site Nijmegen Gerlderland 6532 SZ Netherlands Details
Novartis Investigative Site Hoofddorp 2134 TM Netherlands Details
Novartis Investigative Site Singapore 168583 Singapore Details
Novartis Investigative Site Seoul 03722 South Korea Details
Novartis Investigative Site Seoul 05505 South Korea Details
Novartis Investigative Site Granada Andalusia 18014 Spain Details
Novartis Investigative Site El Palmar Murcia 30120 Spain Details
Novartis Investigative Site Barcelona 08035 Spain Details
Novartis Investigative Site Seville 41013 Spain Details
Novartis Investigative Site Taipei 103616 Taiwan Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field